2,3-dibromo-6,7-dichloroquinoxaline | 239095-84-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-dibromo-6,7-dichloroquinoxaline
• CAS: 239095-84-2
• 化学式: C₈H₂Br₂Cl₂N₂
• 分子量: 356.831
• InChiKey: OWBJCMPWZNHXDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  381.3±37.0 °C(Predicted)
• 密度：
  2.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2,3-dibromo-6,7-dichloroquinoxaline 在 copper diacetate 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 N'-(3-bromo-6,7-dichloro-quinoxalin-2-yl)-N,N-dimethyl-but-2-yne-1,4-diamine
  参考文献：
  名称：

  Synthesis and structure–Activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-Molecule antagonists for interleukin-8 receptor

  摘要：

  Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00399-7
• 作为产物：
  描述：

  2,3-二羟基-6,7-二氯喹喔啉 在 五溴化磷 作用下， 以 sodium hydroxide 、 乙醇 为溶剂， 以94%的产率得到2,3-dibromo-6,7-dichloroquinoxaline
  参考文献：
  名称：

  Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

  摘要：

  喹喔啉化合物以及其制备方法和药物组合物被描述，这些化合物可作为白细胞介素-8（IL-8）受体拮抗剂，并可用于治疗趋化因子介导的疾病，其中趋化因子结合到IL-8a（CXCR1）或b（CXCR2）受体，例如选自牛皮癣、特应性疾病综合征、关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、胃溃疡、脓毒性休克、内毒素休克、革兰氏阴性败血症、毒性休克综合征、中风、心脏和肾脏再灌注损伤、肾小球肾炎或血栓形成，阿尔茨海默病、移植物宿主反应、移植排斥反应或过敏性疾病的趋化因子介导的疾病。

  公开号：

  US06548499B1

文献信息

• Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US06548499B1

  公开（公告）日：2003-04-15

  Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

  喹喔啉化合物以及其制备方法和药物组合物被描述，这些化合物可作为白细胞介素-8（IL-8）受体拮抗剂，并可用于治疗趋化因子介导的疾病，其中趋化因子结合到IL-8a（CXCR1）或b（CXCR2）受体，例如选自牛皮癣、特应性疾病综合征、关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、胃溃疡、脓毒性休克、内毒素休克、革兰氏阴性败血症、毒性休克综合征、中风、心脏和肾脏再灌注损伤、肾小球肾炎或血栓形成，阿尔茨海默病、移植物宿主反应、移植排斥反应或过敏性疾病的趋化因子介导的疾病。
• Synthesis of Novel 3-Substituted Pyrrolo[2,3-<i>b</i>]quinoxalines via an Intramolecular Heck Reaction on an Aminoquinoxaline Scaffold
  作者：Jie Jack Li

  DOI：10.1021/jo9910839

  日期：1999.10.1
• PROTON EXCHANGE MEMBRANES
  申请人：Fuchs Alan

  公开号：US20110033776A1

  公开（公告）日：2011-02-10

  The present invention is directed to proton exchange membranes such as for use in fuel cells. In one embodiment, a polyetherquinoxaline is obtained by reaction between a haloquinoxaline and at least one diol, which forms a repeating unit including an ether linkage. The polyetherquinoxaline is suitable for use in a proton exchange membrane, which can be used in a fuel cell.
• US6548499B1
  申请人：——

  公开号：US6548499B1

  公开（公告）日：2003-04-15
• [EN] SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOXALINE SUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE L'INTERLEUKINE-8
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1999042463A1

  公开（公告）日：1999-08-26

  (EN) Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic dermatitis, disease associated with pathological angiogenesis (i.e. cancer), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.(FR) L'invention porte sur des composés de quinoxaline, ainsi que sur leurs procédés de préparation et leurs compositions pharmaceutiques. Ces composés sont utiles comme antagonistes du récepteur de l'interleukine-8 (IL-8) et peuvent être utilisés dans le traitement d'une maladie induite par la chémokine, la chémokine se fixant à un récepteur d'IL-8a (CXCR1) ou b (CXCR2), telle que le psoriasis ou la dermatite atopique, une maladie associée à l'angiogenèse pathologique (c.-à-d. le cancer), l'asthme, la maladie pulmonaire obstructive chronique, le syndrome de la détresse respiratoire de l'adulte, l'arthrite, la maladie intestinale inflammatoire, la maladie de Crohn, la resto-colite hémorragique, l'ulcère gastrique, le choc septique, le choc endotoxinique, la septicémie à germes Gram négatif, le syndrome de choc toxique, l'ictus, les lésions cardiaques et rénales de perfusion répétée, la glomérulonéphrite ou la thrombose, la maladie d'Alzheimer, la réaction du greffon contre l'hôte, les rejets de greffe allogénique ou les maladies allergiques.